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Abstract
Polycyclic aromatic hydrocarbons (PAHs) are environmental and occupational carcinogens
produced by the incomplete combustion of organic materials, such as coal and petroleum product
combustion, tobacco smoking, and food cooking, that may be significant contributors to the
burden of cardiovascular disease in human populations. The purpose of this study was to
investigate associations between ten monohydroxy urinary metabolites of four PAHs and three
serum biomarkers of cardiovascular disease (fibrinogen, homocysteine, and white blood cell
count). Using data on 3,219 participants aged 20 years and older from the National Health and
Nutrition Examination Survey (NHANES) 2001–2004 dataset, the associations between PAH
metabolites and serum inflammatory markers were analyzed using Spearman correlations and
multiple linear regression modeling. The PAH metabolites of naphthalene, fluorene, phenanthrene,
and pyrene each showed both positive and negative correlations with homocysteine, fibrinogen,
and white blood cell count (correlation coefficient range: −0.077 to 0.143) in nonsmoking
participants. Using multiple linear regression models adjusted for age, gender, race/ethnicity, and
body mass index, estimates of weighted geometric means of inflammatory marker levels were not
significantly different between high and low levels (75th vs. 25th percentiles) for all PAH
metabolites in nonsmoking subjects. The results of this study do not provide evidence for a
relationship between PAH exposure (as measured by urinary levels of PAH metabolites) and
serum biomarkers of cardiovascular disease after controlling for tobacco use.
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1. Introduction
Polycyclic aromatic hydrocarbons (PAH) are environmental and occupational carcinogens
that are produced by the incomplete combustion of organic materials, such as coal and
petroleum product combustion, tobacco smoking, and food cooking (ATSDR, 1995; Bartle,
1991; U.S. Department of Health and Human Services, 2005). In addition to causing cancers
in different organs, exposure to high levels of PAHs has been suggested to contribute to the
development of atherosclerosis and to increased rates of cardiovascular disease in humans
(Burstyn et al., 2005; Tuchsen et al., 1996). Considering the contribution of tobacco smoke
exposure, ambient air pollution, and occupational hazards to cardiovascular morbidity and
mortality, PAHs may be significant contributors to the burden of cardiovascular disease in
human populations.
Evidence from both basic science and public health research has suggested associations
between PAH exposure and cardiovascular disease. Animal studies in various species have
demonstrated that injections of PAHs significantly increase aortic plaque volumes in a dose
dependent relationship, and that chronic PAH exposure significantly increases the number of
inflammatory cells in atherosclerotic plaques (Albert et al., 1977; Curfs et al., 2005; Penn
and Snyder, 1988). Studies investigating the public health impact of exposure to tobacco
smoke and to fine particulate matter air pollution, both of which are known to be sources of
PAHs in human populations, have shown both exposures to be associated with adverse
cardiovascular events (Dominici et al., 2006; Mensah et al., 2005; Peel et al., 2007; Taylor et
al., 1992; Walker et al., 2008). Additionally, employees in occupations with known
exposures to high levels of PAHs have been reported to have an increased risk of ischemic
heart disease and cardiovascular mortality due to cardiovascular disease (Burstyn et al.,
2005; Evanoff et al., 1993; Hansen and Hansen, 1983; Ronneberg and Ronneberg, 1995;
Tuchsen et al., 1996).
One mechanism by which PAHs may play a role in the development of atherosclerosis and
cardiovascular disease is through inflammation. A number of inflammatory factors are
important predictors and possible promoters of atherosclerosis (Wilson et al., 2004). Serum
biomarkers of cardiovascular disease (such as white blood cell count, homocysteine,
fibrinogen, and c-reactive protein) have been investigated in human populations as possible
proximate mechanisms of adverse vascular outcomes and cardiovascular disease. Studies
have shown that an elevated white blood cell count and serum c-reactive protein are
associated with the development of cardiovascular disease (Bassuk et al., 2004; Danesh et
al., 1998; Ridker et al., 2003). Elevated levels of homocysteine are associated with increased
risk of cardiovascular disease while the mechanism is not yet completely elucidated,
increased levels of homocysteine have been associated with impaired fibrinolysis (Tofler et
al., 2002). A large body of evidence has established fibrinogen as an independent risk factor
for cardiovascular disease and as an important mediator through which traditional risk
factors, such as low-density lipoprotein, exert their effects (Kannel and Kannel, 2005). C-
reactive protein has since been found to be associated with high levels of urinary
monohydroxy PAH metabolites, suggesting that PAH exposure may play a role in the
progression of atherosclerosis through inflammation (Everett et al., 2010).
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The purpose of this study was to determine if associations existed between the serum
biomarkers of cardiovascular disease fibrinogen, homocysteine, and white blood cell count
and ten urinary metabolites of four PAHs using data from a study involving a nationwide
probability sample representative of the non-instituitonalized US population.
2. Materials and Methods
Using data from the National Health and Nutrition Examination Surveys (NHANES) 2001–
2004, this study investigated associations between the urinary metabolites of PAHs and
serum biomarkers of cardiovascular disease in a representative sample of the US civilian
population. Conducted by the National Center for Health Statistics, the 2001–2004
NHANES used a complex sampling strategy to obtain a representative sample of the non-
institutionalized U.S. civilian population aged two months or older from 15 US communities
per survey cycle (NHANES, 2008). Participants completed detailed questionnaires, received
physical examinations, and received laboratory analysis of biologic samples.
Measurements of urinary metabolites of PAHs were assessed in participants aged 6 years
and over on a one-third sample of all NHANES participants. Within the database of
NHANES participants from the 2001–2002 and 2003–2004 survey cycles, some participants
did not have complete demographic data to allow for sampling weight calculation needed for
analyses to be representative of the U.S. population. Therefore, for this study, a subsample
of participants were identified who had a) valid sampling weights for use in analyses
adjusting for the complex sampling design of the study and b) were age 20 years or older
since children are believed to have different PAH exposure and metabolism compared to
adults (Cohen Hubal et al., 2000).
White blood cell counts were performed on samples using the Beckman Coulter MAXM
instrument in the Mobile Examination Centers. Homocysteine was measured using
fluorescence polarization immunoassay on the Abbott IMX analyzer. Fibrinogen was
measured by the clot detection technique to determine sample values. All variables (except
for fibrinogen) were available for analysis in all two 2-year survey cycles; fibrinogen was
available only for analysis for the first NHANES cycle (2001–2002).
At the time of this study, data on ten monohydroxy PAH metabolites were available from
the 2001–2004 NHANES survey cycles for analysis. Urinary concentrations of PAH
metabolites were measured by means of capillary gas chromatography combined with high-
resolution mass spectroscopy methods that have been described previously (NHANES,
2001). Urinary concentrations of PAH metabolites were adjusted for urinary creatinine
concentration as was done in the Center for Disease Control’s Third National Report on
Human Exposure to Environmental Chemicals (CDC, 2005).
Additional variables shown to be associated with urinary PAH metabolite levels in past
studies were investigated for inclusion in adjusted linear regression models. These included
age, gender, race/ethnicity, body mass index (BMI) (equal to the weight in pounds divided
by the square of the height in inches), and tobacco smoke exposure (either being a current
smoker or having either home or workplace exposure to secondhand smoke) (Suwan-ampai
et al., 2009). Age, gender, and race were attained by self-report. Race/ethnicity was
classified as Non-Hispanic White, Non-Hispanic Black, Hispanic, and other/mixed race.
BMI was calculated using measured weight and height attained by physical examination.
All statistical analyses were conducted with SAS version 9.2 (SAS institute, Inc., Cary, NC)
using survey procedures that adjusted for the complex survey design and included
appropriate sampling weights developed by the National Center for Health Statistics for this
random subsample to obtain accurate estimates representative of the non-institutionalized
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civilian US population (CDC, 2005). Relationships between demographic characteristics and
inflammatory markers were performed to identify covariates to be used in later analyses.
Due to urinary PAH metabolites having a detection limit, analyses using ranks and
percentiles were performed to properly handle left-censored PAH data. Spearman
correlations were performed to investigate associations between levels of urinary PAH
metabolites and inflammatory markers for current smokers and nonsmokers. Lastly,
associations between urinary PAH metabolites and serum biomarkers of cardiovascular
disease were analyzed using simple linear regression with adjustment for sampling weights.
To investigate possible relationships between PAH metabolite and serum cardiovascular
disease biomarkers in nonsmoking participants geometric mean differences were calculated
for inflammatory markers by the interquartile range (75th vs 25th percentile) of each urinary
PAH metabolite in nonsmoking subjects a multiple linear regression models adjusting the
variables previously shown to be associated with PAH metabolites (age, gender, race, and
BMI).
3. Results
Data on 21,161 NHANES participants were available from the 2001–2004 survey cycles. A
random one-sixth subsample of NHANES participants received laboratory examination of
urine samples for PAHs, for a total of 5,598 subjects. A total of 3,219 participants (57.5% of
PAH subjects; 15.2% of all NHANES subjects) with PAH measurements were age 20 years
or older and had valid sampling weights for inclusion in this analysis. Fibrinogen
measurements were only available for subjects aged 40 years and older and in the 2001–
2002 survey cycle, for a total of 1,008 participants. Sample size and weighted percentages
for demographic characteristics of the NHANES 2001–2004 sample population included in
this analysis are shown in Table 1.
To investigate associations between demographic covariables and serum inflammatory
markers, weighted geometric mean differences of individual inflammatory markers were
calculated by covariate category (Table 2). Mean homocysteine levels were significantly
increased for participants aged 40–59 or 60+ years compared to age 20–39 years; mean
fibrinogen level was significantly increased for age being 60+ years compared to those aged
20–39 years; mean white blood cell count was significantly decreased for age being 40–50
and 60+ years. Female gender was found to be associated with significantly decreased levels
of homocysteine and significantly increased levels of fibrinogen and white blood cell count.
Significant differences in mean levels of all inflammatory markers were seen in at least one
racial category compared to White non-Hispanic subjects. Self-report of being a current
smoker was significantly associated with increased levels of all inflammatory markers.
Lastly, having a BMI defined as either overweight or obese was associated with
significantly increased mean levels of fibrinogen and white blood cell count compared to
normal and underweight subjects.
Spearman correlations of urinary metabolites of naphthalene, fluorene, phenanthrene, and
pyrene with serum cardiovascular disease biomarkersare were performed with stratification
by smoking status (see online appendix, Table A). For homocysteine, current smokers were
found to have weakly yet positive correlations with all urinary PAH metabolites (range:
0.133 to 0.259), while nonsmokers were found to have both positive and negative weak
correlations with PAH metabolites (range: −0.077 to 0.143). For fibrinogen, current smokers
and nonsmokers were found to have both positive and negative weak correlations with
urinary PAH metabolites (smokers: −0.034 to 0.144, nonsmokers: −0.061 to 0.023). For
white blood cell count, current smokers were found to have weak yet positive correlations
with all urinary PAH metabolites (range: 0.024 to 0.118), while nonsmokers were found to
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have both positive and negative weak correlations with PAH metabolites (range: −0.036 to
0.076).
Table 3 shows associations between estimates of adjusted, weighted geometric mean levels
of inflammatory markers by the interquartile range (75th vs. 25th percentile) of
monohydroxy PAH metabolites and serum biomarkers of cardiovascular disease in
nonsmokers using age-adjusted and multiple linear regression models after adjusting
demographic characteristics. For both homocysteine and white blood cell count, elevated
levels of all urinary PAH metabolites were associated with small increases on inflammatory
marker levels that were not statistically significant in nonsmoking subjects in both age-
adjusted and multiple linear regression models (homocysteine range: 0.00 to 0.08, white
blood cell count range: 0.00 to 0.06). For fibrinogen, elevated levels of urinary PAH
metabolites were associated with small increases and decreases in inflammatory marker
levels that were not statistically significant in nonsmoking subjects in both age-adjusted and
multiple linear regression models (range: −0.45 to 2.88).
4. Discussion
The results of this study do not provide evidence for a relationship between PAH exposure
(as measured by urinary levels of PAH metabolites) and serum biomarkers of cardiovascular
disease after controlling for tobacco use. While current smokers were found to have
consistently small yet positive correlations between urinary PAH metabolites with levels of
homocysteine and white blood cell count, this trend in correlations was not seen in
nonsmokers. In the case of fibrinogen, no consistent trend was seen, with both small positive
and negative correlations with urinary PAH metabolites for both smokers and nonsmokers.
In our analysis of nonsmoking subjects using multiple linear regression models, no
statistically significant differences existed in the estimated mean levels of inflammatory
markers between high and low levels (75th vs. 25th percentiles) of each PAH metabolite.
Thus, the results of our analyses do not support the tentative hypothesis that PAH exposure
contributes to cardiovascular disease development.
The results of this study also do not support the hypothesis that environmental exposure to
PAHs, such as with exposure to secondhand tobacco smoke and/or environmental air
pollution, are a significant contributor to the burden of cardiovascular disease via
inflammation in the U.S. population. Past research has shown that exposure to tobacco
smoke, which contains mixtures of PAHs, is associated with elevated levels of serum
biomarkers of cardiovascular disease (Bazzano et al., 2003; Wilkinson et al., 2007).
Similarly, past studies have found that people exposed to high levels of ambient air
particulate matter, which also contains mixtures of PAHs, may have increased levels of c-
reactive protein, fibrinogen, and white blood cells (Ruckerl et al., 2007; Ruckerl et al., 2006;
Schwartz, 2001). While a recent study that used data from the NHANES 2003–2004 found
associations between urinary PAH metabolites and c-reactive protein, believed to be the
most reliable of the inflammatory biomarkers, the results of this study do not provide
additional evidence of such an association (Everett et al., 2010; Pearson et al., 2003). The
lack of associations between urinary metabolites of the PAHs naphthalene, fluorene,
phenanthrene, and pyrene with serum biomarkers of inflammation, however, suggests that
PAH exposure may not be a significant contributor to the development of cardiovascular
disease through an inflammatory mechanism in the US population.
One important strength of this study is that our analysis incorporated 4 years of collected
data (2001–2004) with more than 3,000 adult subjects of a nationally representative sample
of the entire US civilian population whose PAH metabolites were assessed under controlled
conditions. In addition, this study used 3 biomarkers of inflammation as surrogate measures
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of inflammation involved in cardiovascular disease development. However, the cross-
sectional nature of NHANES limits the conclusions that can be made based on the results of
this analysis. Additionally, many statistical tests were performed in our analysis, which may
result in some statistically significant results that may not accurately represent the true state
of tested relationships.
5. Conclusions
In conclusion, the results of this study do not provide evidence for a relationship between
PAH exposure (as measured by urinary monohydroxy PAH metabolites) and serum
biomarkers of cardiovascular disease independent of tobacco smoke exposure.
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Polycyclic aromatic hydrocarbon metabolites are not associated with cardiovascular
biomarkers.
No consistent relationships between exposure and outcome were found independent of
tobacco use.
Polycyclic aromatic hydrocarbon exposure is not a major contributor to cardiovascular
disease.
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     20–39 1,172 39.90% 37.10% - 42.69%
     40–59 989 38.56% 36.10% - 41.01%
     60+ 1,058 21.55% 19.66% - 23.44%
Gender
     Male 1,547 47.87% 45.85% - 49.89%
     Female 1,672 52.13% 50.11% - 54.15%
Race/ethnicity
     White, non-Hispanic 1,701 72.42% 68.16% - 76.68%
     Black, non-Hispanic 632 11.21% 8.87% - 13.56%
     Mexican American 662 7.48% 5.18% - 9.77%
     Other Hispanic 118 4.82% 2.52% - 7.12%
     Other 106 4.07% 2.92% - 5.22%
Tobacco Smoke Exposureb
     Secondhand Smoke Unexposed Nonsmoker 2,122 63.10% 60.06% - 66.15%
     Secondhand Smoke Exposed Nonsmoker 363 12.11% 10.55% - 13.67%
     Current Smoker 731 24.79% 22.33% - 27.25%
Body Mass Index
     Normal/Underweight 1,004 34.35% 31.80% - 36.91%
     Overweight 1,111 33.54% 31.40% - 35.68%
     Obese 1,000 32.10% 29.43% - 34.77%
a
– Sample size varies due to item non-response
b
– Self-reported exposure to secondhand smoke in either the home or the workplace
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